Showing 1 to 1 of 1 results
theglobeandmail.com
🌐 85% Global Worthiness
Optune's Delayed Funding Highlights Flaws in Canada's Drug Approval Process
Despite Health Canada's 2022 approval and a 2017 study showing Optune's effectiveness in extending the lives of glioblastoma patients, its \$27,000 monthly cost and lack of provincial funding create significant delays and inequities in access across Canada.
Optune's Delayed Funding Highlights Flaws in Canada's Drug Approval Process
Despite Health Canada's 2022 approval and a 2017 study showing Optune's effectiveness in extending the lives of glioblastoma patients, its \$27,000 monthly cost and lack of provincial funding create significant delays and inequities in access across Canada.
Progress
56% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results